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A B S T R A C TThere is a need for methodological scrutiny in the economic assess-
ment of personalized medicine. In this article, we present a list of 10
speciﬁc issues that we argue pose speciﬁc methodological challenges
that require careful consideration when designing and conducting
robust model-based economic evaluations in the context of personal-
ized medicine. Key issues are related to the correct framing of the
research question, interpretation of test results, data collection of
medical management options after obtaining test results, and express-
ing the value of tests. The need to formulate the research question
clearly and be explicit and speciﬁc about the technology being eval-
uated is essential because various test kits can have the same purpose
and yet differ in predictive value, costs, and relevance to practice and
patient populations. The correct reporting of sensitivity/speciﬁcity, and
especially the false negatives and false positives (which are population
dependent), of the investigated tests is also considered as a key
element. This requires additional structural complexity to establish
the relationship between the test result and the consecutive treatment
changes and outcomes. This process involves translating the test
characteristics into clinical utility, and therefore outlining the clinical
and economic consequences of true and false positives and true and
false negatives. Information on treatment patterns and on their costssee front matter & 2013 Published by Elsevier Inc
(ISPOR).
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ndence to: Lieven Annemans, Ghent University - Band outcomes, however, is often lacking, especially for false-positive
and false-negative test results. The analysis can even become very
complex if different tests are combined or sequentially used. This
potential complexity can be handled by explicitly showing how these
tests are going to be used in practice and then working with the
combined sensitivities and speciﬁcities of the tests. Each of these issues
leads to a higher degree of uncertainty in economic models designed to
assess the added value of personalized medicine compared with their
simple pharmaceutical counterparts. To some extent, these problems
can be overcome by performing early population-level simulations,
which can lead to the identiﬁcation and collection of data on critical
input parameters. Finally, it is important to understand that a test
strategy does not necessarily lead to more quality-adjusted life-years
(QALYs). It is possible that the test will lead to not only fewer QALYs but
also fewer costs, which can be deﬁned as “decremental” cost per
QALYs. Different decision criteria are needed to interpret such results.
Keywords: guidelines, health economics, modeling, personalized
medicine.
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Personalized medicine is promising from an economic perspec-
tive because in principle only those patients who are most likely
to beneﬁt from a treatment will receive that treatment. It is well
recognized, however, that there is a need for well-structured
economic assessment to provide robust data on the potential
added value of the technology providing the personalized
approach to medicine. This need for methodological scrutiny in
the economic assessment of personalized medicine is consistent
with any evaluation of a health care technology, and there are up
to now very few speciﬁc guidelines available for the economic
assessment of personalized medicine (for an example of a work in
progress, see National Institute for Health and Care Excellence’s
[NICE’s] Diagnostics Assessment Programme) [1]. This lack of
speciﬁc guidance may be viewed to be appropriate given the same
evaluative framework is likely to be generally applicable toidentify and quantify the incremental costs and beneﬁts of a
technology that personalizes medicine. In this article, however,
we present a list of 10 speciﬁc issues that we argue pose speciﬁc
methodological challenges that require careful consideration
when designing and conducting robust model-based economic
evaluations in the context of personalized medicine. The goal of
this article was to discuss these issues with reference to the
standard components of guidelines on the design and conduct of
model-based economic evaluations.
Speciﬁc Issues in Model-Based Economic Evaluations of
Personalized Medicine
In the sections that follow, we describe and suggest solutions to 10
methodological issues that we believe are speciﬁc to the challenge
of conducting robust model-based cost-effectiveness analysis of
technologies designed to personalize medicine. The ultimate goal. on behalf of International Society for Pharmacoeconomics and
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resulting economic evaluation is to provide robust and useful
information for informed resource allocation decisions.
Importance of deﬁning the scope/research question of the
economic evaluation
The ﬁrst step in any guideline for the good design and conduct of
a cost-effectiveness analysis stresses the need to be clear about
the scope of the proposed evaluation (e.g., see Drummond and
Jefferson [2]). In practice, this means deﬁning the research
question and being clear about the technology to be evaluated.
For pharmaceuticals, this step is relatively simple and tends to
involve deﬁning the technology in line with how it will be used as
described in the product license in terms of mode of adminis-
tration, dosing, and frequency. The scope of the evaluation is
then completed by being clear about the relevant comparators,
which should be current practice and may sometimes involve a
“do-nothing” scenario. The eligible study population is then
selected, which drives the subsequent scope of the evaluation.
For companion diagnostic medicines, the process of deﬁning the
technology for evaluation can be more complex and adequate
time and thought should be paid to ensure that the subsequent
evaluation provides information relevant to how the technology
will be used in clinical practice. Understanding the precise nature
will often require the input of expert opinion from laboratory
scientists and other clinicians who may be involved in delivering
the diagnostic component of the combination product. This is
because in most jurisdictions and particularly across Europe, the
diagnostic component is not deﬁned as a particular “product.”
Even in situations in which a biomarker, for example, has been
mentioned within a product license for a particular medicine to
target the eligible population, the technological approach to use
will generally remain unspeciﬁed. Yet, this information is key,
because it will determine the prevalence of the underlying
(genetic) characteristic to be tested and hence the test results.
This also means that it is left to a health service provider in the
implementation stage to select which technology will be used to
identify which biomarker to use in clinical practice. Clearly, this
has implications for deﬁning the technology to be evaluated
within the context of an economic evaluation, in terms of both
the precise nature of the diagnostic and being able to identify a
relevant unit price. Furthermore, the unspeciﬁed nature of the
diagnostic test will also affect the number of potential compara-
tors in the evaluation because it may be necessary to consider
whether the analysis should compare multiple ways of deﬁning
the biomarker as relevant alternatives. This challenge of deﬁning
the technology is exempliﬁed by two health technology assess-
ments relating to CYP2D6 testing for patients taking antipsy-
chotics and tamoxifen. Both health technology assessments were
commissioned on the basis of the availability of a marketed test,
the AmpliChip CYP450 test, which tests for mutations in genes
that encode the drug-metabolizing enzymes CYP2D6 and
CYP2C19 [3,4]. The initial scoping phase and systematic reviewFig. 1 – Example showing three treatment strategies (treof the clinical literature identiﬁed numerous potential technolo-
gies, including bespoke laboratory tests, that could be used to test
for a mutation in the CYP2D6 gene as well as multiple alleles that
may be relevant depending on the ethnicity of the study pop-
ulation. Understanding the actual companion diagnostic to be
evaluated is not an insurmountable challenge but does add
another layer of complexity and analysts should dedicate some
time and resources to ensure that the cost-effectiveness analysis
provides information for decision makers relevant to how the
technology can be used in clinical practice.
Sensitivity, speciﬁcity, false negatives and false positives, and
predictive value need to be considered explicitly
The test is the central component of all clinical applications of
the concept of personalized medicine. The majority of compan-
ion diagnostic tests are much like humans and can and do make
mistakes. Therefore, we need to examine and quantify how these
diagnostic mistakes can impact the health status and costs in the
design and conduct of economic evaluations of personalized
medicine. Sensitivity and speciﬁcity are terms used to describe
the performance (or diagnostic accuracy) of a medical test. When
these terms are used to describe the ability of a medical test to
detect the presence of a speciﬁc disease in a person, sensitivity
refers to the probability that a person with the disease will have a
positive (or abnormal) test result and speciﬁcity refers to the
probability that a person without the disease will have a negative
(or normal) test result. Tests can therefore make two types of
mistakes: one when a patient with the disease has a negative test
result (a so-called false-negative result) and the other when a
patient without the disease has a positive test result (a false-
positive result). But how should these terms be interpreted in the
context of personalized medicine? This can be explained by using
the HER2 test and trastuzumab. Studies have shown that adding
trastuzumab to adjuvant chemotherapy of patients with HER2-
positive breast cancer improves patient survival and reduces the
risk of distant metastases [5]. Figure 1 illustrates the three general
treatment options available: 1) to treat all patients with chemo-
therapy and trastuzumab, 2) to perform a HER2 test ﬁrst and give
chemotherapy and trastuzumab to all patients with a HER2-
positive test result and chemotherapy only to all patients with
a HER2-negative test result, or 3) to treat all patients with
chemotherapy only. There are different ways, however, to assess
the HER2 status of a tumor, including immunohistochemistry
and ﬂuorescence in situ hybridization, and these methods vary in
their ability to establish whether a tumor is HER2-positive or
HER2-negative. Moreover, there is also variation in interpretation
methods. In other words, the different HER2 tests and methods
vary in sensitivity and speciﬁcity; some of the tumors labeled as
HER-positive will actually be HER2-negative (false positive), while
some of the tumors labeled as HER-negative will actually be
HER2-positive (false negative). What does this mean in clinical
practice? The false-positive patients are HER2-negative patients
who will receive, but not beneﬁt from, trastuzumab treatment;at all, test ﬁrst, and treat with chemotherapy only).
F
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possible health loss from the side effects of trastuzumab, and
inconvenience. The false-negative patients are HER2-positive
patients who will not receive trastuzumab treatment even
though it would have been beneﬁcial; this will mean not only
health loss but also some reduced costs (because of not receiving
trastuzumab) and some increase in costs (because of increased
recurrence risk).
In addition, the predictive value of a test should be explicitly
considered. Companion diagnostic tests may actually be rela-
tively sensitive and speciﬁc in terms of being able to identify the
biomarker or genetic mutation being targeted. The importance of
using this biomarker or genetic mutation, in terms of changing
prescribing behavior and subsequent health outcomes, however,
may in practice be minimal because it has a low predictive value.
The concept of predictive value takes into account the prevalence
of the biomarker or mutation in the population and hence, means
that key epidemiological data must also feed into model-based
analysis to allow a true assessment of the positive and negative
predictive value of the companion diagnostic. This combination
of data will enable researchers to evaluate the overall cost-
effectiveness of using a particular test-drug combination versus
not using the drug at all or using the drug without the test.
Figure 2 illustrates the need to consider the prevalence of a
biomarker such as HER-2 in an economic evaluation (using
hypothetical data). If the prevalence of HER2-positive tumors
among breast cancer cases is known to be very low (in the ﬁgure,
o%), then the most cost-effective strategy will be not to use
trastuzumab at all, because this yields the highest net monetary
beneﬁt. Conversely, if the prevalence of the characteristic is
known to be high (in the ﬁgure, >90%), then the most cost-
effective option will be to treat all patients with trastuzumab. If
the prevalence is between 10% and 90%, however, the test-ﬁrst
strategy will be the most cost-effective strategy. Note that the
decision about which strategy is most cost-effective will depend
on properties of the disease, treatment, and test (including its
sensitivity, speciﬁcity, and cost) as well as on the payer’s
willingness-to-pay threshold.
Evaluations of personalized medicine need to incorporate
input parameters such as test sensitivity and speciﬁcity or the
prevalence of a biomarker. It is therefore important to recognize
how best to include them in the model and, perhaps more
importantly, to carefully consider what kinds of values they
could have.
Test characteristics should be translated into clinical utility
Incorporating and capturing the clinical utility (which goes
beyond predictive value) of the test is a vital aspect to include
in an evaluation to understand the added value of a companion300,000
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ig. 2 – Example showing the relationship between the
revalence of a biomarker and the cost-effectiveness of
hree treatment strategies (treat all, test ﬁrst, and treat with
hemotherapy only).diagnostic test. Clinical utility was deﬁned succinctly in the ACCE
model project as “How likely the test is to signiﬁcantly improve
patient outcomes.” The ACCE framework was the ﬁrst publicly
available analytical process proposed for evaluating scientiﬁc
data on emerging genetic tests [6]. The example using HER2-
trastuzumab explicitly illustrates the fact that personalized
medicine has two components: an information or diagnostic
component (the HER2 test result) and an action or therapeutic
component (the decision to treat with either trastuzumab and
chemotherapy or only chemotherapy). The exact link between
the two components is clariﬁed in Figure 1. More importantly, the
value of this link was examined in clinical trials to establish the
effectiveness of trastuzumab in treating HER2-positive breast
cancer tumors. Although the HER2 test was initially viewed as a
prognostic test, where a positive HER2 test result was associated
with an unfavorable prognosis, at the time of the ﬁrst trials of
trastuzumab, a relationship between the HER2 test and respon-
siveness to trastuzumab was discovered during the development
of trastuzumab. This “codevelopment” and demonstration of a
link between HER2 and effectiveness of trastuzumab during the
trial helped to get the drug reimbursed. The HER2-trastuzumab
link is a demonstration of the clinical utility of the test, where
one can clearly see how the test result will affect treatment
choices and patient outcomes. In other cases, often in case of
stand-alone diagnostics, the link between the test result and
treatment choice is not so clear. One reason for this is because
the test is developed separately from a treatment as a stand-
alone test. For example, suppose that a currently used predictive
test for preeclampsia has a speciﬁcity of 95% but a sensitivity of
only 30%. Now assume that a company has developed a new test
with a much higher sensitivity of 80%. This new test, applied in
the ﬁrst quarter of pregnancy, would be able to predict the
occurrence of preeclampsia later on during pregnancy much
better than the current test. While this ability sounds like a great
improvement, it will not lead to any health gain if effective
preventive treatment is not available.
A similar situation has been presented in the case of Alz-
heimer’s disease, whereby it is possible with a genetic test (APOE-
e4 status) to identify patients at risk for early onset of the disease,
but whereby actual preventive treatments are still lacking:
“Although there is no way to change one’s, lifestyle modiﬁcations
may help reduce the potential effects of having APOE-e4. These
lifestyle modiﬁcations include eating a heart-healthy diet, exer-
cising and staying mentally active” [7].
These three examples show that deriving clinical utility is in
some cases (especially companion diagnostic medicines) rather
straightforward to determine, whereas in other cases it appears
to be very difﬁcult, if not impossible.
This issue is not a new one and has been discussed by others
who have deliberated on the best way to assess the value of any
type of medical test. For example, Fryback and Thornbury
stressed that the efﬁcacy of imaging techniques can be described
in different ways, starting with technical accuracy, but continu-
ing on to diagnostic accuracy efﬁcacy, diagnostic thinking efﬁ-
cacy, and therapeutic efﬁcacy, and ending at patient outcome
efﬁcacy (which is in general called effectiveness, and often
expressed in quality-adjusted life-years [QALYs]) and even soci-
etal efﬁcacy (cost-effectiveness) [8].
In that sense, it is clear that the various forms of personalized
medicine, even a HER2-trastuzumab type of personalized medi-
cine, are more complex to assess than a typical pharmaceutical.
The majority of published cost-effectiveness analyses, and par-
ticularly those used to inform national-level decision making by
bodies such as NICE in the United Kingdom, however, tend to
focus on understanding the incremental costs and beneﬁts of
a single technology, such as a pharmaceutical. Evaluating
the economic impact of introducing a companion diagnostic
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United Kingdom, NICE has acknowledged the potential complex-
ity that the evaluation of a diagnostics poses by the introduction
of a discrete appraisal process, the Diagnostics Assessment
Programme, for complex diagnostics [1]. Currently, companion
diagnostic medicines will continue to be appraised using the
NICE Technology Appraisal process with a focus on the added
value of the targeted medicine component. The NICE Technology
Appraisal process, however, tends to assume that the companion
diagnostic will be equivalent to the one used in the clinical
evidence considered in the formation of the NICE guidance in
terms of predictive value and ability to identify the eligible
patient population [9]. In effect, this simpliﬁes the potential
complexity of evaluating a companion diagnostic medicine,
which, by deﬁnition, is neither a simple technology nor a single
technology. As noted earlier, a companion diagnostic medicine
comprises a number of related and linked facets: the diagnostic
test, the interpretation of the test result, the treatment decision,
and the prescription and use of the medicine. The overall
effectiveness of this complex intervention is determined by the
actions of several key players, including, for example, the
prescribing clinician, the laboratory scientist, and the patient.
Each of these key players will introduce a behavioral component
that will affect the effectiveness of the companion diagnostic
medicine over and above the biological and pharmacological
action of the two diagnostic and therapeutic component parts
of personalized medicine.
Having said this, one could argue that the true value of a test
goes beyond the clinical utility. Indeed, the value of knowing a
result as such can also be substantial. This is discussed under
item 9.A combination of tests creates a more complex model and
analysis
The model used in the economic evaluation of personalized
medicine can rapidly become very complex if different tests are
involved, either in a parallel fashion or in a sequential fashion.
This can be handled by showing the true situation at the
beginning of the model and then working with combined sensi-
tivities and speciﬁcities of the (group of) tests. Dilemmas in
treatment can be found even if we ignore the issues of sensitivity,
speciﬁcity, and predictive value. One example can be found with
gene expression proﬁling in the diagnosis of acute myeloid
leukemia. Over the past few years, various gene mutations have
been identiﬁed and their association with prognosis has also
been examined [10]. The clinical utility of this information seems
clear enough. Patients who have a gene mutation associated with
a favorable prognosis can undergo chemotherapy and do not
need stem cell transplantation, while those with a gene mutation
associated with an unfavorable prognosis will undergo more
extreme and costly measures such as an allogeneic stem cell
transplantation to maximize the chance of survival. In some
cases, however, a patient can have two types of mutations (one
with a favorable prognosis and one with an unfavorable prog-
nosis), which leads to the question of how this patient should be
classiﬁed and, clearly more importantly, how this patient should
be treated. The lack of empirical data means that a clinician and
a patient have to make a decision about the best choice.
Documentation about the rationale behind treatment decision
can help in the treatment of similar patients and also improve
the validity and generalizability of future economic evaluations.
The leukemia example involves a dilemma resulting from
multiple tests performed at the same time (in parallel) by means
of a single biochip (AMLproﬁler). Other dilemmas can be found
when tests are performed sequentially and, in some instances,
repeated. This approach is often seen in medicine for differentreasons, including the chance of errors or indeterminate results,
costs, and patient preferences. An economic evaluation of a
personalized medicine strategy involving a series of tests
requires not only a larger decision tree than the one shown and
discussed earlier in Figure 1 but also a good understanding about
which tests will be performed after the initial test, which treat-
ment decisions will be made after the tests are performed, and
the impact of these tests and treatments on costs and health. In
many cases, this information will simply not be found in the
published literature and will have to be collected by means of
physician surveys or interviews.
One illustrative example relates to the use of high-resolution
cardiac computed tomography (CT) imaging to determine
whether or not revascularization is worthwhile. This technology
was one of the ﬁrst to be assessed as part of the NICE Diagnostic
Assessment Programme [11]. The patient population consisted of
patients who could not be scanned by using standard CT scanner
and three different strategies were assessed: 1) a high-resolution
CT scan only, 2) an invasive coronary angiography only, and 3) a
high-resolution CT scan followed by an invasive coronary angiog-
raphy. The third strategy meant that a patient would ﬁrst
undergo a CT scan and then undergo angiography only if the
CT scan was positive. The sensitivity, speciﬁcity, and chance of
false positives and false negatives were all included in the model.
In addition, the costs and health effects of all possible combina-
tions of tests and treatment were calculated. This required a
number of assumptions about if and when a false-negative or
false-positive error was discovered, as well as assumptions about
the treatment and outcomes after its discovery.A more complex analysis usually results in greater uncertainty
(ceteris paribus)
Understanding and quantifying the uncertainty in an economic
model is vital so that a decision maker can understand whether
the ﬁndings are robust, how robust the ﬁndings are, and whether
the results are sufﬁcient to recommend the use of a companion
diagnostic medicine in clinical practice. Health economists and
decision analysts have developed a number of methodologies
designed to capture the impact of different causes of uncertainty
that arise as part of the modeling process such as parameter,
methodological, and structural uncertainty [12]. By now, it is
clear, based on the above-mentioned issues, that the uncertainty
in this ﬁeld of personalized medicine is increased, in terms of
both uncertainty about the model structure and uncertainty
about the inputs. A number of factors can indeed potentially
affect the degree of uncertainty observed when conducting an
economic evaluation of personalized medicine. Some examples
include the likelihood of a complex model structure to accurately
represent the potential patient care pathways, the lack of data
about predictive value, and the need for extensive extrapolation
to model the lifetime costs and beneﬁts of testing to target a
medicine. Furthermore, the quality of the primary data source to
support the clinical effectiveness of a test often results in a
further degree of ﬁrst-order uncertainty caused by the inappro-
priate study design generating the evidence. In general, evidence
to support tests is taken from retrospective studies with rela-
tively small sample sizes. Together with the increased levels of
model complexity, the end result of using this poor evidence base
to populate an economic model is that the results generated have
a higher level of uncertainty than that generally found in model-
based evaluations of pharmaceuticals. The practical implication
for the design and conduct of economic evaluations is that a
robust and systematic approach to quantifying the uncertainties
in the model is required that not only takes account of parameter
uncertainty but also considers the potential impact of structural
and methodological uncertainties. This means that a single
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uncertainty in a model-based evaluation of a personalized med-
icine and it will be necessary to support probabilistic sensitivity
analysis with scenario and structural sensitivity analyses.
The extent of uncertainty in an evidence base has important
implications for the successful implementation of new technol-
ogies into clinical practice. In terms of generating robust models
that produce results sufﬁciently useful for decision making, it is
crucial for a decision analyst to make the distinction between a
technology having no evidence of cost-effectiveness and evi-
dence of not being cost-effective both explicit and transparent.
Decision-making bodies such as NICE use value judgments about
the impact of uncertainty in the evidence base alongside the
threshold range to indicate whether a technology is a cost-
effective use of resources [13]. A technology with a point estimate
incremental cost per QALY of just below £30,000 but with a high
degree of uncertainty is less likely to receive a positive recom-
mendation compared with a technology with a similar cost per
QALY but less variability. The degree of uncertainty is a key factor
affecting the decision on whether the technology is likely to be a
cost-effective use of resources. This has clear implications for
evaluations of personalized medicines, which currently, without
exception, show large degrees of uncertainty in terms of param-
eter and structural aspects of the models. Using the current
evidence base, for example, see health technology assessments
of CYP2D6 testing [4], it is unlikely that a national decision-
making body could support the use of many diagnostic compo-
nents of a companion diagnostic medicine combination. This
lack of an evidence base sufﬁcient for informed decision making
opens up opportunities for manufacturers of tests and pharma-
ceuticals to close the evidence gap and produce data to feed into
reimbursement decision-making processes.Data gaps and the increased need for real-life data
Building further on the above, a recurring theme in the literature
that reports the key challenges in the economic evaluation of
personalized medicine is the impact of data and evidence gaps
[14]. All economic modeling is fraught with difﬁculties associated
with lack of data, and methods are being developed to try and
deal with this enduring issue such as using mathematical
approaches to elicit expert opinion and identify parameter values
and distributions [15]. There are, however, particular types of
evidence gaps that are peculiar to the concept of personalized
medicine. There is especially a paucity of data available that can
be used to populate an economic model that aims to include
some consideration of the impact of subsequent prescribing
behavior and adherence to treatment recommendations. For this
reason, current economic evaluations of companion diagnostic
medicines focus on the health gain from the technology and
assume perfect uptake and use in terms of prescribing practice
[16–18]. In the immediate future, it is likely that these simplifying
assumptions remain for the practical application of economic
evaluation methods in the context of companion diagnostic
medicines. As the diagnostic technologies become more complex
and relevant to more than one medicine or care pathway,
however, these simplifying assumptions are likely to result in
increasingly biased or inaccurate estimates of incremental cost-
effectiveness, which will have a negative impact on the useful-
ness for informed decision making.
Important gaps in information are especially evident with
stand-alone tests. Information on treatment patterns and on its
costs and outcomes is often lacking, especially for false-positive
and false-negative patients. As an example, in the case of
prognostic tests that can identify patients with good or bad
prognosis, the way these patients are managed can largely differ
between centers.The key question then is about how to ﬁll these data gaps. It is
clear from the previous discussion that some of the data required
are not best provided from randomized controlled trial study
designs and prospective cohort studies contained in a patient
registry system are likely to offer another data source required to
show how the use of personalized medicine affects subsequent
treatment pathways and patient outcomes. This implies that
health economists and decision analysts must be prepared to
accept data that have come from sources other than the current
gold standard of the randomized controlled trial. Furthermore, it
is neither fair nor realistic to expect manufacturers to generate all
the data required and health care systems and providers must
consider how they are going to meet the increasing demand
for comparative effectiveness and resource use data generated
from electronic systems of collating and storing patient medical
records.Need for (early) modeling
A key requirement in the development of many technologies is to
conduct early models, that is, models conducted in the early
stages of the development of a technology. Based on an antici-
pated clinical proﬁle of the technology, it can be estimated what
its potential cost-effectiveness will be. For instance, if a new
treatment that is in phase I or II of development is expected to
reduce the number of events by 20%, this anticipated clinical
feature can be put into such a model to estimate the potential
money that can be saved and the potential number of QALYs that
can be gained. Hence, the developers will better understand
whether the technology has the potential to become cost-effec-
tive, given its anticipated price and expected beneﬁts.
The main reason for the use of early models is clear: the
research and development costs of new technologies are known
to be very high and the majority of these development costs
come from late development. Therefore, several important stra-
tegic decisions have to be made during early development. Early
models can be of high use here for many purposes [19].
The ﬁrst application is the input into go/no go and priority
setting decisions by the manufacturer because the results can
reveal that further development of the technology is not inter-
esting from an economic viewpoint, or that developing a certain
technology is more attractive than another. For stratiﬁed medi-
cine, often combining a test and a drug, the question becomes
much more complex because it is about a go/no go decision on
two technologies.
Another frequent application is to guide the decision to focus
the further development in speciﬁc indications or patient groups,
or in a speciﬁc positioning, in which better value for money can
be expected. But it is exactly the nature of a test/drug combina-
tion to test such a population. Hence, the early model again has a
complex task, namely, to ﬁnd out which test-drug combination,
with which features for both, will lead to an optimal selection of
target population that guarantees the best societal outcome as
well as a satisfactory economic situation for the company(ies).
Other early models reveal that the clinical trials should collect
very detailed data on a speciﬁc parameter (e.g., the management
of a given adverse event, the level of compliance), when this
parameter appears to be a very sensitive one in the model. Early
models on stratiﬁed medicine are again much more complex
with this regard because they may again reveal sensitive varia-
bles related to both the test and the drug, eliciting the need for
clinical trials that provide robust estimates on all these variables.
Finally, an early model is also required to assist in the
development of the business case, whereby it needs to be decided
how the added economic value will be distributed between the
test and the drug, that is, what the optimal societally accepted
price for both should be. This requires multidimensional strategic
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both the test and the drug are varied together with the true
prevalence of the mutation or other feature one is looking for.
Interestingly, these analyses can be repeated in the later phases
of development, after more information about the true values of
these parameters has been collected.
In summary, conducting early models for stratiﬁed medicine
puts much more of a burden on modelers than do the traditional
early models for a drug or a device.
Is QALY gain the best way to describe the value of personalized
medicine?
The current cost-effectiveness analysis framework of using
health gain (e.g., QALYs) to describe the value of a complex
health technology such as personalized medicine is not likely to
sufﬁciently capture all its beneﬁts [20]. The idea that the QALY
approach is not ideal is not a new observation, and methodo-
logical work continues to either improve or challenge the appli-
cation of the QALY. A consensus statement by Drummond et al.
[21] presented a way forward and is an indication that most
health economists agree that the QALY as a concept is here to
stay but will undergo continual development and adaptation.
One of the key comments on the QALY is that it often does not
sufﬁciently cover all patient beneﬁts [22]. For the health economic
evaluations of companion diagnostic medicines, the same ques-
tion can be put forward, with a special emphasis on process
utility. The concept of process utility has already been studied for
several years. It can be deﬁned as the satisfaction resulting from
the process of providing a technology rather than the outcome of
the technology. Part of this process, when related to testing, is the
communication of the results and the recommendations regard-
ing the consecutive options. Even if a test result will not lead to
changing treatment, the actual value of receiving the communi-
cation about the results and the associated advice cannot be
ignored. There are, however, currently no available valuation
metrics that can quantify the added value associated with the
process of testing and with knowing its outcomes in addition to
the health gain that may arise from a more effectively targeted
medicine. Contingent valuation methods have been applied but
with variable success.
An alternative approach may be found in the “capability”
theory. Measuring capability recognizes that some types of health
care may have an impact that goes beyond the health of the
individual consuming that health care and even beyond the
process of the health care technology. Capability is more related
to empowerment, the facto being correctly informed, education,
etc. Work is currently ongoing to attach valuation metrics to the
capability measures [23].
What are the implications when personalized medicine reduces
QALYs and costs?
A ﬁnal remark is that it is important to understand that a test
strategy does not necessarily lead to more QALYs. There are
possible cases when the test leads not only to fewer QALYs but
also fewer costs, which can be deﬁned as “decremental” cost per
QALYs [24]. Indeed, if a test still holds some false-negative
results, then some patients are denied treatment from which
they could have beneﬁted. The overall results may be that the
test and treat strategy is not only cheaper (because of not giving
the expensive treatment to many patients) but also offers less
QALYs. Similar dilemmas can be found in the use of cheaper
generic substitutes instead of brand drugs [25]. A related issue is
the threshold that is used for the assessment of the cost-
effectiveness of a new treatment, for example, £30,000 per QALY.
This is a major difference for pharmaceuticals, where the major-
ity of new interventions lead to higher costs and a gain in QALY,and subsequently the assessment of the “additional value for
money” is based on the threshold. The assessment of “less value
for money” and the interpretation of a lower or higher value than
the threshold is not common in health economics and reviewers
are not familiar with it [26]. Therefore, it can be questioned
whether the same rules will be applied for decremental cost per
QALYs as for the standard “incremental” cost per QALYs [24].Discussion and Ways Forward
Personalized medicine has the potential to improve health out-
comes and cost-effectiveness in the health care system. Actual
economic assessments of personalized medicine, however, are
fraught with challenges, and this article has identiﬁed and
discussed a number of them. It should be clear that some of the
challenges discussed here are not unique to personalized medi-
cine. For example, the need to formulate a clear research question
and be very speciﬁc about the technology being evaluated is
discussed in detail in the Cochrane Handbook of Systematic
Reviews of Intervention [27]. Nevertheless, it might be argued that
the severity of these issues is greater only in economic assess-
ments of personalized medicine and other complex interventions
with multiple components. When reviewing the current modeling
guidelines, it will be important to mention the speciﬁc issues
listed in this article and how to deal with them appropriately.
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